CEL-SCI Secures $10 Million to Advance Cancer Immunotherapy

CEL-SCI Corporation has completed a $10 million public offering, with funds to support the development of its cancer immunotherapy, Multikine. Shares were sold at $9.00 each, with ThinkEquity as the sole placement agent. The financing will aid in advancing Multikine and general corporate needs. CEL-SCI is focused on its innovative approach to oncology treatment, leveraging Multikine to strengthen the immune response before traditional cancer therapies.

CEL-SCI Corporation (NYSE American: CVM) has successfully completed a $10 million public offering, with proceeds earmarked to support the development of its innovative cancer immunotherapy, Multikine. The shares were sold at a public offering price of $9.00 each, with ThinkEquity acting as the sole placement agent [1].

The financing will be utilized to advance the continued development of Multikine, as well as for general corporate purposes and working capital. CEL-SCI's focus on boosting the immune system before traditional cancer therapies, such as surgery, radiotherapy, and chemotherapy, positions Multikine as a potential game-changer in the oncology treatment landscape. The company believes that strengthening the immune system at an early stage can significantly enhance the body's ability to fight cancer.

The public offering comes at a strategic time for CEL-SCI, with the company recently receiving Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. This designation further underscores the potential of Multikine to address an underserved patient population with limited treatment options.

The proceeds from the offering will also help CEL-SCI navigate the complex regulatory landscape, ensuring that Multikine can secure necessary approvals and gain access to patients in need. The company's commitment to fiscal discipline, demonstrated through cost-cutting measures and strategic funding decisions, reflects its dedication to delivering value to shareholders and investors.

As CEL-SCI continues to advance Multikine, investors can expect to see a disciplined approach to capital allocation, aligning with the company's long-term goals of unlocking the global potential of its innovative cancer immunotherapy. The strategic timing of the public offering, following the expiration of warrant lock-ups, further highlights CEL-SCI's ability to optimize liquidity while managing investor sentiment [2].

References:
[1] https://www.businesswire.com/news/home/20250829759392/en/CEL-SCI-Announces-Closing-of-%2410-Million-Public-Offering
[2] https://www.ainvest.com/news/cel-sci-corporation-warrant-liquidity-outlook-navigating-post-lock-dynamics-investor-sentiment-2508/